The effect of duloxetine on ECoG activity of absence-epilepsy model in WAG/Rij rats

Year 2019, Volume: 9 Issue: 3, 235 - 239, 30.09.2019

Hatice Aygün

https://doi.org/10.16899/jcm.595608

Abstract

Aim: Many
epidemiological studies have found a high
incidence of depression and anxiety in people with epilepsy. Duloxetine is a selective
inhibitor of serotonin and norepinephrine reuptake (SNRI) and commonly prescribed in a patient with major depressive
disorder. The aim of this study was to investigate
the effect of duloxetine on the WAG/Rij rat in an experimental rat model
of absence-epilepsy.

Methods: WAG/Rij
rats were randomly assigned into 5 groups with 7 animals in each group. Tripolar
electrodes were placed on the skull to
perform electrocorticography (ECoG) evaluation. Then, following the recovery
period, ECoGs were recorded at 09:00 am for 3 hours every day. Subsequently, duloxetine (1, 5, 10
and 30 mg/kg) was injected
intraperitoneally (i.p). After
the treatment program, ECoG recordings were taken for 3 hours. And then all
animal anxiety-like behavior by using the
behavioral test, open field test (OFT) was performed after duloxetine (1,5,10
and 30 mg/kg) treatment. The total number and
the total duration of the spike-wave
discharges (SWDs) were
calculated offline. The
number of squares crossed (locomotor activity) and the duration of grooming
episodes were analyzed in OFT. 

Results: The doses of duloxetine (1 mg/kg) did not alter ECoG and OFT parameters. The 5, 10 and 30 mg/kg doses of duloxetine decreased the total number and the total duration of
SWDs, (p<0.05) and increased the number of squares crossed when
compared to with control group (p <0.05) without changing duration of
grooming episodes (p> 0.05). Intraperitoneal administering of 1 mg/kg
duloxetine did not show any statistically
significant change in regard to the number and duration of SWDs.

Conclusions: In the present study, duloxetine reduce
dose-dependent absences-like seizures and
anxiety-like behavior.

Keywords

Duloxetine, Absence Epilepsy, Waj/Rij Rat, ECoG, Open Field Test

Absans Epilepsi Modeli Olan Waj/Rij Sıçanlarda Duloksetinin ECoG Aktivitesi Üzerine Etkisi

Abstract

Öz

Amaç: Birçok
epidemiyolojik çalışma epilepsili hastalarda yüksek depresyon ve anksiyete
insidansı olduğunu bulmuştur. Duloxetin, serotonin ve norepinefrin geri
alımının seçici bir inhibitörüdür (SNRI) ve genellikle majör depresif bozukluğu
olan hastalara reçete edilir. Bu çalışmanın amacı, absans-epilepsinin deneysel bir
hayvan modeli olan WAG/Rij sıçanlarda epileptiform aktive üzerine duloksetinin
etkisini araştırmaktır.

Yöntem: WAG/Rij sıçanlar her grupta 7 hayvan
bulunan 5 gruba rasgele ayrıldı. Elektrokortikografi (ECoG) değerlendirmesi yapabilmek
için kafataslarına tripolar elektrotlar yerleştirildi. Daha sonra, iyileşme periyodunu
takiben, her sabah saat 09:00'da üç saat bazal ECoG kayıtları alındı. Sonrasında,
duloksetin (1, 5, 10 ve 30 mg/kg) intraperitoneal (i.p) enjekte edildi. Tedavi
programı sonrası, ECoG kaydı 3 saat boyunca alındı. Daha sonra tüm hayvanların anksiyete
benzeri davranışları davranışsal test olan açık alan testi (AAT) ile test
edildi. Diken dalga deşarjlarının (DDD) toplam sayısı ve toplam süresi
hesaplandı. Geçilen karelerin sayısı (lokomotor aktivite) ve grooming
bölümlerinin süresi AAT'de analiz edildi.

Bulgular: Duloksetin (1 mg/kg) dozları ECoG ve AAT
parametrelerini değiştirmedi. İntraperitoneal 1 mg/kg duloksetin uygulaması,
DDD'lerin sayısı ve süresi açısından istatistiksel olarak anlamlı bir
değişiklik göstermedi. 5, 10 ve 30 mg / kg duloksetin dozları kontrol grubuyla
karşılaştırıldığı zaman DDD'lerin toplam sayısını ve süresini azalttı, (p
<0.05) ve grooming süresini değiştirmeksizin geçilen karelerin sayısını
arttırdı.

Sonuç: Sunulan çalışmada, duloksetinin, doza
bağımlı olarak absans benzeri nöbetleri ve anksiyete benzeri davranışları azalttığı
görüldü.

Keywords

Duloksetin, Absans Epilepsi, Waj/Rij Sıçan, ECoG, Açık Alan Testi

References

• 1- Zupec-Kania BA, Spellman E. An overview of the ketogenic diet for pediatric epilepsy. Nutr Clin Pract. 2009;23(6):589-596.
• 2- Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008;13(Suppl. 1): S1–29.
• 3- Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336-2344.
• 4- Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006;129(Pt 3):617-624.
• 5- Cardamone L, Salzberg MR, O'brien TJ, Jones NC. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?. British J Pharmacol 2013;168(7):1531-1554.
• 6- Citraro R, Leo A, De Fazio P, et al. Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive‐like behavior in the WAG/Rij rat model of absence epilepsy. Br J Pharmacol 2015;172(12):3177-3188.
• 7- Esen M, Aygun H. The effect of duloxetine on penicillin-induced epileptiform activity in rats. Neurological Res 2019;41(4):298-305.
• 8- Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacol 1993;8(1):23–33.
• 9- van Luijtelaar G, Zobeiri M. Progress and outlooks in a genetic absence epilepsy model (WAG/Rij). Curr Med Chem 2014;21:704–721.
• 10- Sarkisova K, van Luijtelaar G. (2011) The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression. Prog Neuropsychopharmacol Biol Psychiatry In press.
• 11- Aygun H, Aydin D, Inanir S, Ekici F, Ayyildiz M, Agar E. The effects of agomelatine and melatonin on ECoG activity of absence epilepsy model in WAG/Rij rats. Turkish J Biology 2015;39: 904-910.
• 12- Aygun H, Ayyildiz M, Agar E. Swimming exercise decreases the absence-like epileptic activity in WAG/Rij rats. Behav Brain Res 2019;363:145-148.
• 13- Jobe PC, Browning RA. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 2005;7(4):602e619
• 14- Santos Jr JG, do Monte FH, Russi M, et al. Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats. Braz J Med Biol Res 2002;35(4):469-472.
• 15- Borowicz KK, Gołyska D, Luszczki JJ, et al. Effect of acutely and chronically administered venlafaxine on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model. European J Pharmacol 2011;670(1):114-120
• 16- Ahern TH, Javors MA, Eagles DA, et al. The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacol 2006;31:730–738.
• 17- Kruse SW, Dayton KG, Purnell BS, et al. Effect of monoamine reuptake inhibition and α1 blockade on respiratory arrest and death following electroshock‐induced seizures in mice. Epilepsia 2019;60(3):495-507.
• 18- Zomkowski AD, Engel D, Cunha MP, Gabilan NH, Rodrigues ALS. The role of the NMDA receptors and L-arginine–nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test. Pharmacol Biochem Behav 2012;103(2):408-417.
• 19- Sun YH, Dong YL, Wang YT, et al. Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis. PloS one 2013;8(10):e76603.
• 20- Grégoire S, Michaud V, Chapuy E, et al. (2012). Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin. Pain 2012;153(8):1657-1663.
• 21- Cui R, Wang L, Liu L, Ruan H, Li X. Effects of noradrenergic and serotonergic systems on risk-based decision-making and center arena activity in open field in rats. Eur J Pharmacol 2018;841:57-66.
• 22- Sasamori H, Ohmura Y, Yoshida T, Yoshioka M. Noradrenaline reuptake inhibition increases control of impulsive action by activating D1-like receptors in the infralimbic cortex. . Eur J Pharmacol 2019;844:17-25.
• 23- Sarkisova K, Kulikov MA, Kudrin VS, et al. Neurochemical mechanisms of depression-like behavior in WAG/Rij rats. Zh Vyssh Nerv Deiat Im I P Pavlova 2013;63(3):303-315.
• 24- Midzyanovskaya IS, Kuznetsova GD, Coenen AM, et al. Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats. Brain Res 2001;91:62–70.
• 25- Sarkisova KYu, Midzyanovskaya IS, Kuznetsova GD, van Luijtelaar G. The involvement of the brain dopaminergic system in the pathogenesis of absence seizures and depressive-like behavioral alterations in WAG/Rij rats. FENS Abstr 2006;3:A024-29.
• 26- Sarkisova KYu, Kulikov MA, Midzyanovskaya IS, Folomkina AA. Dopamine-dependent character of depressive-like behavior in WAG/Rij rats with genetic absence epilepsy. Zh Vissh Nervn Dejat 2007;57:91–102.
• 27- Depaulis A, van Luijtelaar G. Genetic models of absence epilepsy in the rat. In: Pitkanen A, Schwartzkroin P, Moshe S, editors. Animal models of seizures and epilepsy. San Diego: Elsevier Inc; 2006. p. 233–248.
• 28- Wilner AN, Sharma BK, Thompson A, et al. Diagnoses, procedures, drug utilization, comorbidities, and cost of health care for people with epilepsy in 2012. Epilepsy & Behav. 2014;41:83e90.